The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)
Showing 1-13 of 13 articles
Long-term clinical outcomes of everolimus-eluting bioresorbable scaffolds versus everolimus-eluting stents: final five-year results of the AIDA randomised clinical trial
Kerkmeijer L,
Renkens M,
Tijssen R,
Hofma S,
van der Schaaf R,
Arkenbout EK,
Weevers A,
Garcia-Garcia HM,
Kraak R,
Piek JJ,
Tijssen J,
Henriques J,
de Winter R,
Wykrzykowska JJ
March 18, 2022 | 10.4244/EIJ-D-21-00419
Outcomes of bioresorbable vascular scaffolds versus everolimus-eluting stents by coronary complexity: a sub-analysis of the AIDA trial
Kraak R,
Tijssen R,
van Dongen I,
Elias J,
Hofma S,
van der Schaaf R,
Arkenbout EK,
Weevers A,
Tijssen J,
Piek JJ,
de Winter R,
Henriques J,
Wykrzykowska JJ
December 4, 2020 | 10.4244/EIJ-D-18-00884
Impact of ticagrelor monotherapy on two-year clinical outcomes in patients with long stenting: a post hoc analysis of the GLOBAL LEADERS trial
Takahashi K,
Chichareon P,
Modolo R,
Kogame N,
Chang C,
Tomaniak M,
Moschovitis A,
Curzen N,
Haude M,
Jung W,
Holmvang L,
Garg S,
Tijssen J,
Wykrzykowska JJ,
de Winter R,
Hamm C,
Steg PG,
Stoll H,
Onuma Y,
Valgimigli M,
Vranckx P,
Windecker S,
Serruys P
October 23, 2020 | 10.4244/EIJ-D-19-00498
Bioresorbable vascular scaffold versus metallic drug-eluting stent in patients at high risk of restenosis: the COMPARE-ABSORB randomised clinical trial
Smits P,
Chang C,
Chevalier B,
West N,
Gori T,
Barbato E,
Tarantini G,
Kocka V,
Achenbach S,
Dudek D,
Escaned J,
Wlodarczak A,
Abdel-Wahab M,
Esposito G,
Tijssen J,
Morice M,
Onuma Y,
van Geuns R
October 23, 2020 | 10.4244/EIJ-D-19-01079
Ticagrelor monotherapy beyond one month after PCI in ACS or stable CAD in elderly patients: a pre-specified analysis of the GLOBAL LEADERS trial
Tomaniak M,
Chichareon P,
Modolo R,
Takahashi K,
Chang C,
Kogame N,
Spitzer E,
Buszman P,
van Geuns R,
Valkov V,
Steinwender C,
Geisler T,
Prokopczuk J,
Sabaté M,
Zmudka K,
Rademaker-Havinga T,
Tijssen J,
Jüni P,
Hamm C,
Steg PG,
Onuma Y,
Vranckx P,
Valgimigli M,
Windecker S,
Baber U,
Anderson R,
Dominici M,
Serruys P
April 3, 2020 | 10.4244/EIJ-D-19-00699
Patient-oriented composite endpoints and net adverse clinical events with ticagrelor monotherapy following percutaneous coronary intervention: insights from the randomised GLOBAL LEADERS trial
Serruys P,
Tomaniak M,
Chichareon P,
Modolo R,
Kogame N,
Takahashi K,
Chang C,
Spitzer E,
Walsh S,
Adlam D,
Hildick-Smith D,
Édes I,
van de Harst P,
Krackhardt F,
Tijssen J,
Rademaker-Havinga T,
Garg S,
Steg PG,
Hamm C,
Jüni P,
Vranckx P,
Onuma Y,
Verheugt F
December 20, 2019 | 10.4244/EIJ-D-19-00202
Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent in routine PCI: three-year clinical outcomes from the AIDA trial
Kerkmeijer L,
Tijssen R,
Hofma S,
van der Schaaf R,
Arkenbout K,
Kraak R,
Weevers A,
Piek JJ,
de Winter R,
Tijssen J,
Henriques J,
Wykrzykowska JJ,
Ijsselmuiden A,
Kauer F,
Beijk M,
Vis M,
Koch K
September 20, 2019 | 10.4244/EIJ-D-19-00325
Complete two-year follow-up with formal non-inferiority testing on primary outcomes of the AIDA trial comparing the Absorb bioresorbable scaffold with the XIENCE drug-eluting metallic stent in routine PCI
Tijssen R,
Kraak R,
Hofma S,
van der Schaaf R,
Arkenbout EK,
Weevers A,
Elias J,
van Dongen I,
Koch K,
Baan Jr J,
Vis M,
de Winter R,
Piek JJ,
Tijssen J,
Henriques J,
Wykrzykowska JJ
July 20, 2018 | 10.4244/EIJ-D-18-00335
Implantation techniques (predilatation, sizing, and post-dilatation) and the incidence of scaffold thrombosis and revascularisation in lesions treated with an everolimus-eluting bioresorbable vascular scaffold: insights from the AIDA trial
Tijssen R,
Kraak R,
Elias J,
van Dongen I,
Kalkman D,
Nassif M,
Sotomi Y,
Asano T,
Katagiri Y,
Collet C,
Piek JJ,
Henriques J,
de Winter R,
Tijssen J,
Onuma Y,
Serruys P,
Wykrzykowska JJ
July 20, 2018 | 10.4244/EIJ-D-17-01152
Optical coherence tomography findings: insights from the “randomised multicentre trial investigating angiographic outcomes of hybrid sirolimus-eluting stents with biodegradable polymer compared with everolimus-eluting stents with durable polymer in chronic total occlusions” (PRISON IV) trial
Teeuwen K,
Spoormans E,
Bennett J,
Dubois C,
Desmet W,
Ughi G,
Belmans A,
Kelder J,
Tijssen J,
Agostoni P,
Suttorp MJ,
Adriaenssens T
August 4, 2017 | 10.4244/EIJ-D-17-00261
Latest news
AHEAD OF PRINT
LVOT calcification in TAVI : a post hoc analysis from the SOLVE-TAVI trial
FREE ARTICLE - Serdar Farhan et al
August 9, 2022
NEW ISSUE
The 16th EBC Expert consensus; ticagrelor or aspirin monotherapy 1 year after PCI; vasospasm and atherosclerosis in ANOCA; lifetime valve journey; and more…
August 5, 2022
AHEAD OF PRINT
RADIANCE-HTN SOLO 36-month analysis
FREE ARTICLE - Florian Rader et al
August 1, 2022
AHEAD OF PRINT
Percutaneous left atrial appendage closure with superior vascular access
FREE ARTICLE - Roberto Galea et al
August 4, 2022
AHEAD OF PRINT
Dual ProGlide vs ProGlide and FemoSeal after TAVI
FREE ARTICLE - Jonas M.D. Gmeiner et al
July 29, 2022
AHEAD OF PRINT
Stent thrombosis in comatose OHCA (ST-OHCA Study)
FREE ARTICLE - Martin Rauber et al
July 25, 2022
AHEAD OF PRINT
Evolocumab and periprocedural microvascular damage
FREE ARTICLE - Masaharu Ishihara et al
July 15, 2022